Human papillomavirus infection in Egyptian esophageal carcinoma: Correlation with p53, p21waf, mdm2, C-erbB2 and impact on survival

Pathology International

Volumn 55, Issue 2, 2005, Pages 53-62

  Bahnassy, Abeer A ^a   Zekri, Abdel Rahman N ^a,b   Abdallah, Samira ^b   El Shehaby, Amal M R ^b   Sherif, Ghada M ^b  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

C erbB2; Esophagus; HPV; mdm 2; p21waf; p53; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EGYPT; ESOPHAGUS CARCINOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, NEOPLASM; EGYPT; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14844322405     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01804.x     Document Type: Article

References (47)

1. Togawa K, Jaskiewicz K, Takahashi H, Meltzer SJ, Rustgi AK. Human papillomavirus sequences in esophageal squamous cell carcinoma. Gastroenterology 1994; 107: 128-36.
2. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis. (Review.) Int J Cancer 1996; 69: 225-35.
3. de Villiers EM, Lavergne D, Chang F et al. An interlaboratory study to determine the presence of human papillomavirus DNA in esophageal carcinoma from China. Int J Cancer 1999; 12: 225-8.
4. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 19: 594-606.
5. Syrjanen KJ. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch Geschwulstforsch 1982; 52: 283-92.
6. Smits HL, Tjong-A-Hung SP, ter Schegget J, Nooter K, Kok T. Absence of human papillomavirus DNA from esophageal carcinoma as determined by multiple broad spectrum polymerase chain reactions. J Med Virol 1995; 46: 213-15.
7. Poljak M, Cerar A, Seme K. Human papillomavirus infection in esophageal carcinomas: a study of 121 lesions using multiple broad-spectrum polymerase chain reactions and literature review. (Review.) Hum Pathol 1998; 29: 266-71.
8. Lavergne D, de Villiers EM. Papillomavirus in esophageal papillomas and carcinomas. Int J Cancer 1999; 1: 681-4.
9. Matsha T, Erasmus R, Kafuko AB, Mugwanya D, Stepien A, Parker MI. CANSA/MRC Oesophageal Cancer Research Group. Human papillomavirus associated with oesophageal. cancer. J Clin Pathol 2002; 55: 587-90.
10. Fidalgo PO, Cravo ML, Chaves PP, Leitao CN, Mira FC. High prevalence of human papillomavirus in squamous cell carcinoma and matched normal esophageal mucosa: assessment by polymerase chain reaction. Cancer 1995; 1: 22-8.
11. Yang G, Zhang Z, Liao J et al. Immunohistochemical studies on Waf1p21, p16, pRb and p53 in human esophageal carcinomas and neighboring epithelia from a high-risk area in northern China. Int J Cancer 1997; 4: 746-51.
12. Taniere P, Martel-Planche G, Puttawibul P et al. TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand. Int J Cancer 2000; 15:223-7.
13. Furihata M, Ohtsuki Y, Ogoshi S, Takahashi A, Tamiya T, Ogata T. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int J Cancer 1993; 8: 226-30.
14. Yasuda M, Kuwano H, Watanabe M, Toh Y, Ohno S, Sugimachi K. p53 expression in squamous dysplasia associated with carcinoma of the oesophagus: evidence for field carcinogenesis. Br J Cancer 2000; 83: 1033-8.
15. Morgan RJ, Newcomb PV, Hardwick RH, Alderson D. Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma. Eur J Surg Oncol 1999; 25: 364-7.
16. Shibagaki I, Tanaka H, Shimada Y et al. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin Cancer Res 1995; 1: 769-73.
17. Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999; 12: 580-86.
18. Lam KY, Tin L, Ma L. C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 1998; 24: 431-5.
19. Polkowski W, van Sandick JW, Offerhaus GJ et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999; 6: 290-97.
20. Hamilton SR, Aaltonen LA. WHO classification tumor of the digestive system. In: Cabbert HE, Shimoda T, Haimaut P, Nakamura Y, Field JK, Inoue H, eds. Tumours of the Oesophagus. France: IARC Press Lyon, 2000; 9-36.
21. Shirakawa Y, Naomoto Y, Kimura M et al. Topological analysis of p21WAF1/CIP1 expression in esophageal squamous dysplasia. Clin Cancer Res 2000; 6: 541-50.
22. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1999; 20: 129-34.
23. Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 20: 1350-54.
24. Kleter B, van Doorn LJ, Schrauwen L et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 2508-17.
25. Khaled HM, Bahnassi AA, Zekri AR, Kassem HA, Mokhtar N. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol 2003; 21: 334-41.
26. Chang F, Syrjanen S, Shen Q, Ji HX, Syrjanen K. Human papillomavirus (HPV) DNA in esophageal precancer lesions and squamous cell carcinomas from China. Int J Cancer 1990; 45: 21-5.
27. Li Y, Huang G, Xiao H, Huang Y, Mao T, Deng W. The status of human papillomavirus 16 DNA in the tissues of human esophagus carcinoma. Hua Hsi I Ko Ta Hsueh Hsueh Pao 1991; 22: 157-60.
28. Chang F, Shen Q, Zhou J et al. Detection of human papillomavirus DNA in cytologic specimens derived from esophageal precancer lesions and cancer. Scand J Gastroenterol 1990; 25: 383-8.
29. Cooper K. p53 mutations in human papillomavirus-associated oesophageal squamous cell carcinoma. Br J Cancer 1995; 72: 1337.
30. Hale MJ, Liptz TR, Paterson AC. Association between human papillomavirus and carcinoma of the oesophagus in South African blacks. A histochemical and immunohistochemical study. S Afr Med J 1989; 76: 329-30.
31. Cooper K, Taylor L, Govind S. Human papillomavirus DNA in oesophageal carcinomas in South Africa. J Pathol 1995; 175: 273-7.
32. Turner JR, Shen LH, Crum CP, Dean PJ, Odze RD. Low prevalence of human papillomavirus infection in esophageal squamous cell carcinomas from North America: analysis by a highly sensitive and specific polymerase chain reaction-based approach. Hum Pathol 1997; 28: 174-8.
33. Kawaguchi H, Ohno S, Araki K et al. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000; 60: 2753-5.
34. Kim R, Clarke MR, Melhem MF et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997; 42: 2453-62.
35. Khurshid A, Kazuya N, Hanae I, Manabu I. Infection of human papillomavirus (HPV) and Epstein-Barr virus (EBV) and p53 expression in human esophageal carcinoma. J Pak Med Assoc 1998; 48: 138-42.
36. Vos M, Adams CH, Victor TC, van Helden PD. Polymorphisms and mutations found in the regions flanking exons 5-8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet 2003; 140: 23-30.
37. Soontrapornchai P, Elsaleh H, Joseph D, Hamdorf JM, House AK, Iacopetta B. TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value. Eur J Cancer 1999; 35: 1683-7.
38. Breton J, Sichel F, Abbas A, Marnay J, Arsene D, Lechevrel M. Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). Mutagenesis 2003; 18: 299-306.
39. Osugi H, Morimura K, Okuda E et al. p53 null mutations detected by a p53 yeast functional assay predict a poor outcome in young esophageal carcinoma patients. Int J Oncol 2002; 21: 637-41.
40. Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis 2003; 24: 1039-44.
41. Bennett WP, Hollstein MC, He A et al. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991; 6: 1779-84.
42. Wagata T, Shibagaki I, Imamura M et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinoma. Cancer Res 1993; 53: 846-50.
43. WAF proteins in gastric and esophageal cancers. Comparison with mutations of the p53 gene. Dig Dis Sci 1998; 43: 279-89.
44. Ozawa S, Ando N, Kitagawa Y, Ueda M, Kitajima M. Molecular alterations in Barrett's esophagus and adenocarcinoma. (Review.) Nippon Geka Gakkai Zasshi 1999; 100: 235-9. (In Japanese.)
45. Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J. Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterol Clin Biol 1995; 19: 465-74.
46. KIP1. Histopathology 2001; 39: 589-96.
47. Zekri A-R N, Bahnassy AA, Shaarawy SM et al. Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. J Med Microbiol 2000; 49: 3-6.